Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813130 | 1.00 | P2RX7 (0.44) | P2RX7HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL16339048 | 1.00 | P2RX7 (0.44) | P2RX7HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL159149 | 0.88 | ACE (0.47) | P2RX7ACE | |
| SCHEMBL1587617 | 0.88 | ACE (0.47) | P2RX7ACE | |
| SCHEMBL1850331 | 0.88 | ACE (0.47) | P2RX7ACE | |
| SCHEMBL647325 | 0.88 | ACE (0.47) | P2RX7ACE | |
| SCHEMBL18212789 | 0.87 | ACE (0.36) | P2RX7HDAC3HDAC1HDAC2HDAC10 | |
| Ammonia Solution, Strong SCHEMBL11295703 | 0.86 | ACE (0.46) | P2RX7ACE | |
| SCHEMBL13949150 | 0.84 | P2RX7 (0.44) | P2RX7HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL17979454 | 0.76 | ACE (0.45) | ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103732577-B | As effective hdac inhibitor carrying lactams thio derivative and they as medicine purposes | 希格马托制药工业公司 | 2017-04-05 | — | — | CN | claimed |
| EP-2758371-B1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2016-06-15 | — | — | EP | claimed |
| US-8927533-B2 | Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-06 | — | — | US | claimed |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911652-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | Biogen MA Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210051963-A1 | METHODS AND COMPOSITIONS TO IMPROVE PLANT HEALTH AND/OR PLANT PERFORMANCE | Plant Response, Inc. | 2021-02-25 | — | — | US | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| CN-103732577-B | As effective hdac inhibitor carrying lactams thio derivative and they as medicine purposes | 希格马托制药工业公司 | 2017-04-05 | — | — | CN | disclosed |
| EP-2758371-B1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2016-06-15 | — | — | EP | disclosed |
| US-8927533-B2 | Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210051963-A1 | METHODS AND COMPOSITIONS TO IMPROVE PLANT HEALTH AND/OR PLANT PERFORMANCE | GET3, PAH, ITPA | P2RX7 2289/4885HDAC3 1844/4885HDAC1 2339/4885 |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | P2RX7 795/4885HDAC3 645/4885HDAC1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.